Results 101 to 110 of about 194,414 (305)

Establishing the diagnosis of 22q11.2 microdeletion syndrome in congenital heart disease is now an imperative

International Journal of Cardiology Congenital Heart Disease, 2021
Alexandra Arvanitaki, Michael A. Gatzoulis   +1 more
doaj   +1 more source

Effect of pulmonary hypertension on outcome of pulmonary tuberculosis

International Journal of Mycobacteriology, 2015
Objectives: Pulmonary hypertension is a serious disorder with catastrophic outcomes. This study aimed to evaluate the effect of pulmonary arterial hypertension on the outcome among new cases of pulmonary tuberculosis.
Majid Marjani, Payam Tabarsi, Parvaneh Baghaei, Afshin Moniri, Majid Malekmohammad   +4 more
doaj  

Plasma adrenomedullin peptides and precursor levels in pulmonary arterial hypertension disease severity and risk stratification

Pulmonary Circulation, 2020
Adrenomedullin is a potent vasodilatory peptide, linked to pulmonary arterial hypertension pathology. Proximity extension assays were utilized to study plasma biomarkers related to vasoregulation, with focus on adrenomedullin peptides and precursor ...
Habib Bouzina, Göran Rådegran
doaj   +1 more source

Risk factors for hemoptysis in idiopathic and hereditary pulmonary arterial hypertension.

, 2013
INTRODUCTION: When hemoptysis complicates pulmonary arterial hypertension (PAH), it is assumed to result from bronchial artery hypertrophy. In heritable PAH, the most common mutation is in the BMPR2 gene, which regulates growth, differentiation and ...
Tio, D., Leter, E.M., Harm Jan Bogaard, Boerrigter, B.G., Darryl Tio, Anco Boonstra, Edward Leter, Vonk-Noordegraaf, A., Anton Vonk-Noordegraaf, Bart Boerrigter, Bogaard, H.J., Boonstra, A.   +11 more
core   +1 more source

Impact of Evolving Treatment Patterns on Interstitial Lung Disease Progression in Systemic Sclerosis Using the European Scleroderma Trials and Research Database

Arthritis &Rheumatology, EarlyView.
Objective The treatment landscape for systemic sclerosis‐associated interstitial lung disease (SSc‐ILD) has evolved with increasingly available immunosuppressive therapies (ISTs) and antifibrotic treatments. However, their real‐world use remains unclear.
Corrado Campochiaro, Marie‐Elise Truchetet, Madelon Vonk, Giacomo De Luca, Giovanna Cuomo, Lidia P. Ananieva, Eric Hachulla, Vanessa Smith, Ana Maria Gheorghiu, Radim Becvar, Patricia Carreira, Nicolas Hunzelmann, Daniel E. Furst, Vera Ortiz‐Santamaria, Francesco Del Galdo, Marco Matucci‐Cerinic, Anna‐Maria Hoffmann‐Vold, EUSTAR collaborators   +17 more
wiley   +1 more source

Diaphragm weakness in pulmonary arterial hypertension: role of sarcomeric dysfunction

, 2012
Item does not contain fulltextWe previously demonstrated that diaphragm muscle weakness is present in experimental pulmonary arterial hypertension (PH). However, the nature of this diaphragm weakness is still unknown. Therefore, the aim of this study was
Stienen, G.J.M., van Hees, H.W.H., Vonk-Noordegraaf, A., Hees, H.W.H. van, Vonk Noordegraaf, A., Manders, E., de Man, F.S., Ottenheijm, C.A.C., Handoko, M.L., Westerhof, N., Stienen, G.J.   +10 more
core   +1 more source

Immune Complexes Shape the Pathogenicity of Autoantibodies in Systemic Autoimmune Diseases: Insights From an FcγRIIIA‐Reporter Assay

Arthritis &Rheumatology, EarlyView.
Objective Immune complexes (ICs), formed by autoantigen and autoantibody, play a pathogenic role in systemic autoimmune diseases through stimulation of Fcγ receptors (FcγR). However, studies investigating bioactivity of circulating ICs across various diseases remain limited.
Koji Suzuki, Masaru Takeshita, Yuki Imai, Hiroyuki Fukui, Kazunori Furuhashi, Kotaro Matsumoto, Jun Kikuchi, Keiko Yoshimoto, Yuko Kaneko   +8 more
wiley   +1 more source

Integrated Clinical and Proteomic Profiling of CD19 Chimeric Antigen Receptor T Cell Therapy in Progressive Systemic Sclerosis

Arthritis &Rheumatology, EarlyView.
Objective To characterize the clinical, immunologic, and proteomic changes associated with CD19 chimeric antigen receptor T cell therapy in patients with progressive systemic sclerosis (SSc). Methods Patients with progressive SSc received CD19 chimeric antigen receptor (CAR)‐T cell therapy and were observed longitudinally for safety, clinical efficacy,
Chenhan Jia, Wanyi Lin, Zhangyi Zhao, Fenglin Wu, Chaoyu Gu, Yuankai Sun, Zhe Ding, Chang Wei, Xinyu Li, Cuiwei Xie, Peng Xia, Zhen Xia, Xuesong Liu, Shaoying Yang, Chunyan Zhang, Hanlin Yin, Liangjing Lu   +16 more
wiley   +1 more source

The Novel Treatment Options For Pulmonary Arterial Hypertension

, 2021
Pulmonary arterial hypertension is a life threating disease.prior to therapy development the disease mortality was very high and prognosis was poor.
Dahbour, May
core  

Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia. [PDF]

, 2003
BACKGROUND\ud \ud Mutations of the transforming growth factor beta (TGFbeta) receptor components ENDOGLIN and ALK-1 cause the autosomal dominant vascular disorder hereditary haemorrhagic telangiectasia (HHT).
Flanagan, J A, Gruenig, E, Sankelo, M, Halme, M, Elliott, C G, Laitinen, T, Morrell, N W, Trembath, R C, Räisänen-Sokolowski, A, Olschewski, H, Harrison, R E, Robbins, I M, Kermeen, F, Abdalla, S A, Rowell, J, Machado, R D, McLaughlin, V   +16 more
core   +1 more source